Although chronic obstructive pulmonary disease (COPD) is a major global health problem with a rising incidence and morbidity, few pharmacotherapeutic advances have been made over the past several decades. Indacaterol is a novel long-acting β2-adrenoceptor agonist that is available for the maintenance treatment of airflow obstruction in adult COPD patients. The onset of bronchodilation after inhalation of indacaterol is fast. Indacaterol has a 24-h bronchodilatory effect, which allows for once-daily administration. In some large-scale clinical trials, patients who received indacaterol had a significantly higher mean trough forced expiratory volume in 1 second (FEV1) than placebo recipients. COPD exacerbations and symptoms, and health-related quality of life were also significantly improved. Indacaterol was generally well tolerated. It is a new choice for the treatment of COPD.%慢性阻塞性肺疾病(COPD)的发病率和死亡率正逐渐增高,并且已成为全球的一个主要健康问题,但在过去几十年中关于它的药物治疗进展却很缓慢.β2-肾上腺素能受体激动剂可以改善COPD患者症状,是主要治疗药物.茚达特罗是一种新型长效β2-肾上腺素能受体激动剂,临床用于中重度COPD患者稳定期的维持治疗.其起效迅速、作用持续时间长,每日只需给药1次.大规模临床研究显示茚达特罗可以明显改善患者第1秒用力呼气容积(FEV1),减少COPD急性发作,改善呼吸困难症状,提高生活质量,并具有良好的耐受性,为COPD的治疗提供新的选择.
展开▼
